Design and analysis of unit cost estimation studies: How many hospital diagnoses? How many countries?
暂无分享,去创建一个
Daniel Polsky | Henry A Glick | H. Glick | D. Polsky | S. Orzol | Joseph F. Tooley | J. Mauskopf | Sean M Orzol | Joseph F Tooley | Josephine O Mauskopf
[1] K. Schulman,et al. Results of the Economic Evaluation of the FIRST Study: A Multinational Prospective Economic Evaluation , 1996, International Journal of Technology Assessment in Health Care.
[2] H. Glick,et al. Economic Evaluation of the Randomized Aldactone Evaluation Study (RALES): Treatment of Patients with Severe Heart Failure , 2004, Cardiovascular Drugs and Therapy.
[3] R. Willke,et al. Economic Analysis of Tirilazad Mesylate for Aneurysmal Subarachnoid Hemorrhage: Economic Evaluation of a Phase III Clinical Trial in Europe and Australia , 1998, International Journal of Technology Assessment in Health Care.
[4] M. Johannesson,et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. , 1997, The New England journal of medicine.
[5] R. Tretiak,et al. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[6] Erry,et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.
[7] P Carlsson,et al. Resource costing for multinational neurologic clinical trials: methods and results. , 1998, Health economics.
[8] B. Kinosian,et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. , 1995, Journal of cardiac failure.
[9] J. Mauskopf,et al. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy , 1998, Neurology.
[10] H. Glick,et al. Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin’s and non-Hodgkin’s lymphoma , 1998, Bone Marrow Transplantation.
[11] C. Legendre,et al. VALACICLOVIR PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN RENAL TRANSPLANTATION: AN ECONOMIC EVALUATION , 2000, Transplantation.